What if clinical trial participants didn't have to travel hundreds of miles to a research site every few weeks? What if they could participate from home — monitored by wearables, connected through telemedicine, consenting digitally?
That's not a hypothetical. It's happening now. And the market behind it is growing fast.
The global decentralized clinical trials (DCT) market was valued at $8.8 billion in 2024 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR.
The drivers are structural, not cyclical. Regulators in the U.S., Europe and Asia-Pacific are actively building frameworks that support remote trial conduct. Digital health infrastructure — e-consent platforms, remote monitoring, telemedicine — has matured to the point where decentralized approaches are practical at scale. And the industry's push for greater patient diversity and access is making DCTs a strategic imperative, not just a convenience.
North America leads with 46% of the market, but adoption is accelerating globally. The competitive landscape is dynamic, with players like Medidata, Veeva Systems, Medable and Clario building integrated digital trial ecosystems that connect sponsors, sites and patients.
The integration of AI, wearable biosensors and predictive trial management tools is adding another layer of capability — and competitive differentiation.
Want the full picture? Download the free overview of our report Decentralized Clinical Trials: Global Markets for complete market segmentation, competitive analysis and technology assessment.
Download the Free Report Overview →